3 Cheap Stocks Under $100 That Look Like Absolute Steals Right Now
Pinterest, United Parcel Service, and Comcast are some of the cheapest big-name stocks you can buy right now.
They all trade at low earnings multiples and can be strong long-term investments.
10 stocks we like better than Pinterest ›
If you don't want to chase all-time highs and buy stocks at extremely high valuations, the good news is that there are many decently priced options. And below, I'm going to focus on what I think are some of the best deals available.
Three stocks that trade at less than $100 per share and can be bargain buys right now include Pinterest (NYSE: PINS), United Parcel Service (NYSE: UPS), and Comcast (NASDAQ: CMCSA). A couple are facing concerning headwinds, but here's why they can all be great long-term investments.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Pinterest is a popular social media site where people go for ideas related to just about anything. Whether it's home renovation projects, baking, or recent shopping hauls, there's a ton of content to sift through. The platform is particularly popular with Gen Z, which Pinterest says accounts for more than 40% of its monthly user base.
Entering this week, shares of Pinterest have been trading around $35, and that's with the stock rising 24% since the start of the year. And yet, it's still a cheap buy, trading at just 13 times its trailing earnings.
Its price/earnings-to-growth multiple, or PEG, is around 0.8. That's based on analyst expectations over the next five years, and it implies that Pinterest is one heck of a cheap growth stock.
The company's top line rose by 17% in its most recent quarter (which ended on June 30), to just under $1 billion. Monthly active users rose by 11% to 578 million. With a market cap of only $24 billion, Pinterest is a business that could get a whole lot more valuable given how popular it is with younger audiences. It can be a terrific long-term buy.
United Parcel Service
There's not much growth happening for United Parcel Service these days. The logistics company is battling significant macroeconomic headwinds due to tariffs. It's trading at less than $90, and the last time you could have bought the stock at a much cheaper price than that was in 2013.
UPS is facing some near-term challenges, but it's hard to not like the business over the long haul. The world of e-commerce is still getting bigger, and demand for global shipments isn't likely to slow down. There may be short-term adversity, but if you're a long-term investor, you don't need to worry too much about UPS given its dominance in the industry.
The company is making tough but smart decisions, such as scaling back on volume from Amazon in an effort to improve profitability. And it is profitability, not simply sales, that should drive decisions. Although it may not be a popular move and it may hurt the top line, if it improves profit margins, that could be a big win in the end.
UPS is trading at a price-to-earnings multiple (P/E) of 13, and in the long run it could have plenty of upside as economic conditions improve.
Comcast
Rounding out this list of cheap stocks is media and tech company Comcast. It's trading around $34, and its P/E is less than 6 -- an astoundingly low valuation for one of the largest entertainment companies in the country.
Its high debt load (around $100 billion) is undoubtedly turning away a lot of risk-averse investors. But with Comcast spinning off many cable TV networks later this year, that could help reduce costs and allow it to focus on higher-growth opportunities in areas such as streaming. The business may have become too bloated, and simplifying its approach could work well for investors.
Overall, Comcast still has excellent brands in its portfolio, and it's highly profitable, with an operating margin of around 20% over the past six months. I'm optimistic that by becoming leaner, the business can be better positioned for growth in the future. At such a cheap valuation, it may be too tempting to pass up since it offers an excellent margin of safety.
Should you invest $1,000 in Pinterest right now?
Before you buy stock in Pinterest, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pinterest wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!*
Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 18, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
18 minutes ago
- Globe and Mail
Citadel's Rubner Says Retail Momentum Is Structural, Not Cyclical
Citadel Securities strategist Scott Rubner sees retail traders pulling back from their heavy pace of stock buying in September, before resuming activity later in the year. Individual investors have been net buyers of equities in 16 of the past 18 weeks and net buyers of equity options for 16 consecutive weeks, according to Citadel data. Rubner called the trend 'structural, not cyclical,' suggesting the momentum reflects deeper consumer engagement with markets rather than a short-term fad. Historically, retail flows slow during late summer, with September marking the weakest month of participation since 2017, Citadel data shows. Rubner argued that this year will follow a similar pattern, with buying intensity easing after robust June and July inflows. Still, he expects demand to return by year-end, echoing a pattern where persistent dip-buying has repeatedly supported market recoveries. The phenomenon has drawn increasing attention from Wall Street, given retail investors' growing influence on indices like the S&P 500. Market Overview: Retail traders net buyers of stocks in 16 of past 18 weeks Options activity hit 98th percentile, 34% above 12-month average September historically marks retail's weakest participation month Key Points: Citadel's Rubner says buying surge is structural, not cyclical Retail dip-buying lifted S&P 500 from April swoon to records Top investor favorites include Tesla, Nvidia, and UnitedHealth Looking Ahead: Participation likely to wane through September before rebounding Wall Street watching retail flows for market direction signals Recent IPOs like CoreWeave, Circle, and Bullish attract retail demand Bull Case: Citadel's finding that retail flows are 'structural, not cyclical' points to a durable, secular rise in individual investor participation—meaning retail demand can act as an ongoing stabilizer, repeatedly cushioning pullbacks and contributing to upward momentum when institutional appetites fade. Persistent net buying of stocks and equity options, even through softer sentiment data and historically slower periods, suggests that today's retail investors are more engaged, informed, and liquidity-providing than previous generations, offering a counterweight to volatility during corrections. The consistent pattern of retail dip-buying—lifting markets out of recent swoons and repeatedly supporting S&P 500 recoveries—gives bulls confidence that setbacks will be met with fresh inflows as seasonal slowdowns reverse heading into year-end. Diversification of retail interest to both blue-chip favorites (Tesla, Nvidia, UnitedHealth) and newly public equities (CoreWeave, Circle, Bullish) broadens market participation and can drive deeper, more liquid trading even among newer listings and smaller caps. For portfolio construction: Proactive engagement with this influential cohort—through educational content, targeted research, or robust digital trading tools—can help asset managers, brokers, and fintechs capture expanding retail flows and adapt to evolving liquidity dynamics. Bear Case: While retail flows have supported markets recently, seasonal data show that September reliably brings a steep drop in participation—the weakest since 2017—raising the risk of shallow liquidity, sharper swings, or more pronounced drawdowns if institutional conviction falters at the same time. Extreme options activity (at the 98th percentile and 34% above trend) may point to crowded, momentum-driven trades that could unwind quickly if sentiment shifts, leaving retail traders exposed to rapid reversals and higher volatility. Structural engagement does not immunize markets from crowded positioning: if top retail favorites (like Tesla and Nvidia) face negative headlines, retail unwinds could exacerbate selling pressure, especially for recently IPOed names where liquidity is thinner. The rise in retail participation—while generally positive for democratized markets—complicates traditional liquidity and volatility models, making it harder for banks, hedge funds, and policy makers to predict correction depth, institutional buybacks, or the pace of recovery during sharp moves. Action for risk managers and trading desks: Closely monitor retail positioning through broker data, options flows, and social sentiment—apply scenario analysis to hedge liquidity gaps, and prepare playbooks for rapid unwinds if 'buy-the-dip' behavior weakens or if macro shocks emerge as retail flows ebb in the fall. Retail enthusiasm remains evident despite softer consumer sentiment data, with 71 million options contracts trading in a single day last week. Interactive Brokers data showed Tesla (TSLA), Nvidia (NVDA), and UnitedHealth (UNH) among the most purchased names, while retail traders also piled into newly public companies such as CoreWeave and Circle. Analysts note that retail positioning has become a key component of market resilience, cushioning pullbacks and complicating efforts to assess the depth of institutional influence. Even as the market braces for seasonal slowdowns, the persistence of individual investor flows highlights a structural shift in trading behavior. Rubner's thesis suggests retail demand could remain a durable pillar of equity markets, challenging traditional assumptions about volatility and liquidity. For banks, hedge funds, and policymakers alike, tracking this cohort's participation is becoming as critical as monitoring institutional flows.
Globe and Mail
41 minutes ago
- Globe and Mail
Gold is Gaining Momentum on Calls for an Aggressive Interest Rate Cut in September
Distributed on behalf of Trident Resources Corp. Gold mining stocks have outperformed the price of gold this year, according to UBS, as highlighted by Investopedia. They added that UBS analysts noted that miners are enjoying 'some time in the sunshine' after a 'poor track record in recent years.' All of which is great news for related stocks, such as Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF), Newmont Corporation (NYSE: NEM) (TSX: NGT), Barrick Mining (NYSE: B) (TSX: ABX), Franco-Nevada Corp. (NYSE: FNV), and B2Gold Corp. (NYSE AMERICAN: BTG) (TSX: BTO). Fueling more momentum, U.S. Treasury Secretary Scott Bessent believes the Federal Reserve will cut interest rates by half a point at its September meeting. As he told Bloomberg, 'I think we could go into a series of rate cuts here, starting with a 50-basis point rate cut in September. If you look at any model [it suggests that] we should probably be 150, 175 basis points lower.' At the moment, the odds we'll see a sizable rate cut are now up to 93.3%, according to the CME FedWatch tool, which you can see here. Again, it should all have a positive impact on gold and related stocks, such as: Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF) Trident Resources Corp. just announced detailed plans for its upcoming inaugural drill program at the Contact Lake Gold Project in Saskatchewan's underexplored and prolific La Ronge Gold Belt. Trident enters this program with over CAD $11 million in cash and marketable securities, fully funding this drill program and positioning the Company to act swiftly on future exploration opportunities across its Saskatchewan portfolio. Contact Lake Project Location Map: "With drilling to be underway within the next week, we are excited to build on our proven track record of discovery and resource growth in the La Ronge Gold District. We believe our gold assets have the potential to become a tier 1 project in Canada and provide a strong foundation for value creation. We are also optimistic that our systematic exploration methodology will deliver success with additional new discoveries in our underexplored district scale land package,' said Jonathan Wiesblatt, CEO of Trident. The drill program at the Contact Lake mine site will comprise of 5,000 metres across 16 holes with the aim of confirming and extending gold mineralization along strike and down-dip from the historically defined gold mineral resources. The Contact Lake mine was operated by Cameco between December 1994 to May 1998 when 1,006,673 tonnes of ore were processed at a head grade of 6.16 grams per tonne (g/t) Au for a reported 188,185 ounces of gold (Au) recovered with life of mill recovery rate stated at 95%. Contact Lake hosts significant underground infrastructure and exploration potential in the areas immediately adjacent to the underground development. Cameco reported that substantial historically defined gold resources were left in the ground when mining activities were terminated at a time when the gold price was approximately $300/ounce. Contact Lake Gold Project Plan View: The Contact Lake deposit is hosted within the northeast trending Bakos shear zone, which cuts through the granitic portion of the Little Deer Lake composite pluton. The auriferous Bakos shear zone has been drill-defined at between 15 to 40 metres in width over a strike length of greater than 2 km. The 2025 drilling will focus on extending gold mineralization between the underground development and the unmined resources of the BK3 zone, located immediately northeast of the former mine site. Drilling will also target down-dip extensions of the high-grade gold mineralization of the main zone as these types of shear-hosted gold deposits commonly extend at depth providing strong discovery potential below the currently defined dimensions of the Contact Lake deposit. Cyr Drilling from Winnipeg, Manitoba, has been chosen as the drill contractor and is mobilizing their personnel and drill equipment to Contact Lake. All drill cores will be logged, photographed and processed on site throughout the program. Data collection will include geologic, geotechnical and a full 48 element analytical suite in conjunction with a comprehensive QA / QC program with lab-certified standards, field blanks and duplicates comprising >10% of the sample stream. All 2025 data will be incorporated into the existing Contact Lake database and utilized in future exploration programs on the project. Location Map of Planned Drill Holes: The initial drill holes of the 2025 program will be focused on the discovery of shallow gold mineralization immediately northeast of the Contact Lake Main Zone (MZ1), which produced the majority of gold resources during mining operations. The second phase of drilling will target zones at moderate depth (200-250 metres below surface) that lie between the MZ1 zone and the BK3 zone. The BK3 zone is located 150 metres northeast of MZ1, below the western edge of Contact Lake and is reported to host substantial gold resources that were never mined. The final phase of the 2025 drill program will target the down-plunge extension of the gold mineralization in both the MZ1 and MZ2 zones. Drilling will target the heart of the past-producing Contact Lake Mine, following up on historical high-grade intercepts including: Other related developments from around the markets include: Newmont announced second quarter 2025 results, an additional $3.0 billion share repurchase program and declared a dividend of $0.25 per share. "Newmont delivered a strong second quarter, producing approximately 1.5 million attributable gold ounces and generating an all time record quarterly free cash flow of $1.7 billion, underscoring the strength of our world-class portfolio and the disciplined execution of the commitments we shared at the beginning of the year," said Tom Palmer, Newmont's Chief Executive Officer. "We remain firmly on track to achieve our 2025 guidance as we continue to strengthen our safety culture, stabilize our operations and deliver long term value to shareholders." Five years after its formation, the Twiga partnership between Barrick Mining Corporation and the government of Tanzania continues to redefine the role of mining in national development, delivering shared value, operational excellence and long-term investment in the country's future. 'When we established Twiga, it was about more than just resolving legacy issues. It was about building a new future by unlocking Tanzania's gold endowment in a way that fairly shares the benefits and builds lasting value for all stakeholders. Five years on, we've not only re-established Barrick as the sector's leading economic contributor but have also earned national recognition across a range of areas from safety and local content to education and infrastructure,' Barrick president and chief executive Mark Bristow said. Franco-Nevada Corp. CEO Paul Brink just noted, 'I am very pleased with our record financial results this quarter,' stated Paul Brink, CEO. Our portfolio largely produced as expected for the quarter and higher gold prices contributed to record revenue, operating cash flow, Adjusted EBITDA margins and earnings. We also saw constructive developments in Panama, including the shipment of the remaining copper concentrate from Cobre Panama. During the quarter, we acquired a royalty on IAMGOLD's Co^te´ Gold Mine, one of Canada's newest large-scale gold mines and, post quarter-end, a royalty on AngloGold's Arthur Project, one of the largest gold discoveries in Nevada. We anticipate new contributions from Co^te´ and growing contributions from Porcupine and Tocantinzinho to be the main drivers for higher GEOs in the second half of the year. Our acquisitions over the last 18 months have positioned us for strong long-term growth that may be further enhanced by a potential restart at Cobre Panama.' B2Gold Corp. announced its operational and financial results for the second quarter of 2025. Consolidated gold production in the second quarter of 2025, including pre-commercial production from the Goose Mine, was 229,454 ounces, higher than expected. The Fekola, Masbate and Otjikoto mines all exceeded expected production in the second quarter, and the Company remains on track to meet its consolidated annual production guidance range. All three operations continue to meet or exceed gold production expectations to start the third quarter of 2025. Consolidated cash operating costs, excluding pre-commercial production from the Goose Mine, were $745 per gold ounce produced ($762 per gold ounce sold) during the second quarter of 2025. Cash operating costs per ounce produced for the second quarter of 2025 were better than expected as a result of lower than expected fuel costs and higher than expected gold production. On August 7, 2025, B2Gold's Board of Directors declared a cash dividend for the third quarter of 2025 of $0.02 per common share (or an expected $0.08 per share on an annualized basis), payable on September 23, 2025, to shareholders of record as of September 10, 2025. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Trident Resources Corp. by Trident Resources Corp. We own ZERO shares of Trident Resources click here for disclaimer. Contact:
Cision Canada
an hour ago
- Cision Canada
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development. MUMBAI, India, Aug. 21, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support. "We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite," said Peter DeYoung, CEO, Piramal Global Pharma. "This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too." "By investing in Piramal Pharma Solutions' Sellersville facility, we are enabling the manufacture of FDC with exceptional precision and efficiency to meet the future commercial demand," said Douglas Kling, COO, NewAmsterdam Pharma. "We are excited to continue growing alongside our trusted partner, Piramal Pharma Solutions, and thrilled about the potential for our collaboration to benefit countless patients around the globe." Patients aren't the only beneficiaries of this investment. Over the next five years, the suite is expected to create more than 20 new jobs at the Sellersville site, further contributing to the local economy and workforce. This investment underscores the commitment to continuous improvement shared by Piramal Pharma Solutions and NewAmsterdam Pharma. By adding the new production suite, both companies can operate with greater efficiency and capacity, ultimately bringing the FDC product, if approved, to more patients in need. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. The Company seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.
